Skip to Content
Merck

Non-peptide NK1 receptor ligands based on the 4-phenylpyridine moiety.

Bioorganic & medicinal chemistry (2011-03-23)
Germano Giuliani, Andrea Cappelli, Mario Matarrese, Valeria Masiello, Elia Anna Turolla, Cristina Monterisi, Ferruccio Fazio, Maurizio Anzini, Galla Pericot Mohr, Daniela Riitano, Federica Finetti, Lucia Morbidelli, Marina Ziche, Gianluca Giorgi, Salvatore Vomero
ABSTRACT

The quinoline nucleus of the previously described 4-phenylquinoline-3-carboxamides NK(1) receptor ligands 7 has been transformed into either substituted or azole-(i.e., triazole or tetrazole) fused pyridine moieties of compounds 9 and 10, respectively, in order to obtain NK(1) receptor ligands showing lower molecular weight or higher hydrophilicity. The program of molecular manipulations produced NK(1) receptor ligands showing affinity in the nanomolar range. In particular, 4-methyl-1-piperazinyl derivative 9j showed an IC(50) value of 4.8 nM and was proved to behave as a NK(1) antagonist blocking Sar(9)-SP-sulfone induced proliferation and migration of microvascular endothelial cells. Therefore, compound 9j has been labeled with [(11)C]CH(3)I (t(1/2)=20.4 min, β(+)=99.8%) starting from the corresponding des-methyl precursor 9i using with a radiochemical yield of about 10% (not decay corrected) and a specific radioactivity>1 Ci/μmol in order to be used as a radiotracer in next PET studies.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
4-Phenylpyridine, 97%